0.51
-0.0288(-5.34%)
Currency In USD
| Previous Close | 0.54 |
| Open | 0.56 |
| Day High | 0.56 |
| Day Low | 0.51 |
| 52-Week High | 1.92 |
| 52-Week Low | 0.49 |
| Volume | 306,339 |
| Average Volume | 349,598 |
| Market Cap | 10.9M |
| PE | -0.53 |
| EPS | -0.97 |
| Moving Average 50 Days | 0.58 |
| Moving Average 200 Days | 0.98 |
| Change | -0.03 |
If you invested $1000 in Longeveron Inc. (LGVN) since IPO date, it would be worth $6.9 as of February 06, 2026 at a share price of $0.511. Whereas If you bought $1000 worth of Longeveron Inc. (LGVN) shares 3 years ago, it would be worth $12.81 as of February 06, 2026 at a share price of $0.511.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
GlobeNewswire Inc.
9 hours ago
Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron The Mikaela Naylon Give Kids a Chance Act reauthorizes the Pediatric Priority Review Voucher (PPRV) Program and extends eligibility for
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
GlobeNewswire Inc.
Jan 29, 2026 2:15 PM GMT
Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Executive Chairman, Longeveron The patent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue,
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
GlobeNewswire Inc.
Jan 26, 2026 2:15 PM GMT
ELPIS II top-line trial results are anticipated in the third quarter of 2026Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated if ELPIS II results are positiveU.S. FDA has awarded laromest